vTv Therapeutics shares soar on licensing tie-up with Chinese group Newsoara Biopharma

Newsoara will develop vTv Therapeutics' HPP737 as a new treatment for chronic obstructive pulmonary disease
map of China
VTv Therapeutics' main PDE4 inhibitor is called HPP737

vTv Therapeutics (NASDAQ:VTVT) has sold licensing rights to a rival Chinese biotechnology group Newsoara Biopharma, paving the way for Newsoara to develop and commercialize its PDE4 Inhibitor program, which addresses inflammatory diseases, across China and much of the rest of Asia.

The clinical biopharmaceutical company's main PDE4 inhibitor is called HPP737; it aims to treat respiratory illnesses such as chronic obstructive pulmonary disease (COPD) and other inflammatory diseases.

Under the deal’s terms, Newsoara will develop HPP737 and market it in China, Hong Kong, Macau, Taiwan, Thailand, Vietnam, Indonesia, Cambodia, Laos and South Korea.

The tie-up is being applauded by investors, who sent vTv shares up 21.6% to US$2.02 in afternoon trade.

READ: Shares of vTv Therapeutics skyrocket on Alzheimer's Phase 3 trial results

“With this partnership, we hope to develop a new treatment for inflammatory diseases, including COPD, which is one of the major health care burdens in China, with over eight percent of the country’s adult population suffering from the disease and limited safe and effective treatment options available,” said Dr Li, chief executive of Newsoara.

In return for these licensing rights, vTv Therapeutics will receive an undisclosed upfront payment and be eligible for development and commercialization milestone payments as well as sales royalties.

“This represents our second partnership to introduce potential new therapies into the China market which speaks to the importance of that market,” said Steve Holcombe, chief executive of vTv Therapeutics.

vTv has a pipeline of drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as the treatment of inflammatory disorders.

View full VTVT profile View Profile

vTv Therapeutics Inc Timeline

Related Articles

researcher filling a vial
April 23 2018
2018 is shaping up to be a crucial year for the company's drug pipeline
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
Vial of pills
May 17 2018
Cosmos is a modern company, but the trade routes it relies on are ancient

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © personabelovo.ru, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.